Personal Data

Home Address: 330 I Street SE

Washington, DC 20003

202-641-1856

Office Address: Children’s National Medical Center

                                    Center for Cancer and Blood Disorders

111 Michigan Ave NW

                                    Washington, DC 20010

Phone: 202-476-5697

Fax: 202-476-5685

                                    hmeany@childrensnational.org

Date of Birth:                 December 4, 1972

Place of Birth:               Cleveland, Ohio

Citizenship:                   United States

Education

1991-1995        The College of William and Mary

Williamsburg, Virginia

Bachelor of Science in Chemistry

1996-2000        Ohio State University College of Medicine and Public Health

Columbus, Ohio

                        Doctor of Medicine

2000-2003        Columbus Children’s Hospital

Columbus, Ohio

                        Pediatric Intern and Resident

2003- 2006       Children’s National Medical Center

Washington, DC

Pediatric Hematology Oncology Fellow

2004-2006        Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health

Bethesda, Maryland

Pediatric Hematology Oncology Research Fellow

Additional Training

2004                 BioTRAC course on Flow Cytometry, Foundation for the Advanced Education in the Sciences, National Institutes of Health

Bethesda, Maryland

2004-2005        Principles of Clinical Pharmacology, National Institutes of Health

Bethesda, Maryland

2005                 ASCO-AACR Methods in Clinical Cancer Research Workshop

Vail, Colorado

Employment

1994                                   Clinical Research Assistant

                                          Department of Genetics

                                          MetroHealth Medical Center

                                          Cleveland, OH

1995 -1996                         Research Assistant

                                          Case Western Reserve University School of Medicine

                                          Cleveland, OH

June 2006 – June 2009 Clinical Associate, Attending Physician

                                          Children’s National Medical Center, Department of Hematology/Oncology

                                          George Washington University School of Medicine

                                          Washington, DC

                                          Clinical Research Associate

                                          Pediatric Oncology Branch, National Cancer Institute

                                          National Institutes of Health

                                          Bethesda, Maryland

July 2009 – August 2012     Clinical Research Associate

                                         Pediatric Oncology Branch, National Cancer Institute

                                         National Institutes of Health

                                         Bethesda, Maryland

July 2009 – 2015                 Assistant Professor, Attending Physician

                                          Children’s National Medical Center, Department of Hematology/Oncology

                                          George Washington University School of Medicine

                                          Washington, DC

September 2015- present Associate Professor, Attending Physician

                                          Director, Solid Tumor Program

                                          Pediatric Hematology-Oncology Fellowship Program Director

                                          Children’s National Medical Center, Department of Hematology/Oncology

                                          George Washington University School of Medicine

                                          Washington, DC

Professional Licenses

Board Certified, Pediatrics: October 21, 2003

Board Certified, Pediatric Hematology Oncology: November 16, 2006

            Recertification March 2016

District of Columbia Medical License: July 2003- present

Professional Organizations and Committees

2003-present    Children’s Oncology Group: Member

• Neuroblastoma Disease Committee Member
• Committee Member, ANBL0621, A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children with Relapsed or Refractory Neuroblastoma
• Study Chair, ANBL1232, Phase III trial for upfront therapy in patient with newly diagnosed neuroblastoma entitled ‘Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma’

2004-2006        American Society of Hematology: Member

2006-present    American Society of Clinical Oncology: Member

Industry Sponsored Duties

2008-2015        ‘A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children with Solid Tumors’

Sponsor: Amgen

Institutional principal investigator

Administrative Duties and University Duties

2004- 2006       Care Delivery Committee

Center for Cancer and Blood Disorders, Department of Hematology-Oncology Children’s National Medical Center

2004- 2006       American Society of Hematology Trainee Council member

2007-present    Institutional Review Board Member

Children’s National Medical Center

2009-2012        Assistant Fellowship Director

Center for Cancer and Blood Disorders, Department of Hematology-Oncology Children’s National Medical Center

2010-2019        Subcommittee on Approval of Preprinted Orders Member

Center for Cancer and Blood Disorders, Department of Hematology-Oncology Children’s National Medical Center

2012-present    Fellowship Program Director

Center for Cancer and Blood Disorders, Department of Hematology-Oncology

Children’s National Medical Center

2013-2020        Developmental Therapeutics Committee Member

Center for Cancer and Blood Disorders, Department of Hematology-Oncology

Children’s National Medical Center

2015-2016        Pediatric Hematology-Oncology Terminology Working Group Member

Pediatric Terminology Harmonization Initiative

National Institute of Child Health and Human Development

National Institutes of Health

2015- present   Director, Solid Tumor Program

Center for Cancer and Blood Disorders, Department of Hematology-Oncology

Children’s National Medical Center

Educational Achievements

Awards

Power of One Award- Children’s National Medical Center award given monthly to a staff member who has demonstrated themselves to be a champion of children’s health, advocate of their cause, and protector of their future. This nomination was from a family and selected from many by the Safety and Service Power of One coaches.

Grant Morrow III, M.D. Award- Columbus Children’s Hospital, Department of Pediatrics award for academic achievement and involvement in research during residency training

Janet M Glasgow Memorial Award- American Medical Women’s Association award for academic achievement during residency training

Lisa Gunyula Award of Excellence- Columbus Children’s Hospital, Department of Pediatrics award to the pediatric resident who most exemplifies academic, clinical and professional excellence in pediatrics

Children’s Hospital Resident Child Advocacy Award- awarded in 2003 and 2004

Alpha Omega Alpha Honor Medical Society

Grant Support

Title: A Phase 1 Trial and Pharmacokinetic Study of Talabostat (PT-100, Val-Boro-Pro) in Combination with Temozolomide or Carboplatin in Pediatric Patients with Relapsed or Refractory Solid Tumors Including Brain Tumors

Funding Agency: American Society of Clinical Oncology Young Investigator Award

Dates of Award: 07/01/06 – 06/30/07

Yearly Direct Costs of Award: $50,000

Role: Study principal investigator

Percent effort: 50%

Title: Phase 1 Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients with Relapsed or Refractory Solid Tumors

Funding Agency: American Society of Clinical Oncology Career Development Award

Dates of Award: 07/01/09 – 06/30/12

Yearly Direct Costs of Award: $66,666

Role: Study principal investigator

Percent effort: 50% (for study in total)

Title: Phase 1 Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients with Relapsed or Refractory Solid Tumors

Funding Agency: The Pablove Foundation, Childhood Cancer Research Grant

Dates of Award: 07/01/11 – 06/30/13

Yearly Direct Costs of Award: $50,000

Role: Study principal investigator

Percent effort: 50% (for study in total)

Title: Phase 1 Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients with Relapsed or Refractory Solid Tumors

Funding Agency: Clinical and Translational Science Institute- Children’s National, Research Award for Pilot Feasibility Studies/Development of Research Methodologies/Development of New Research Technology

Dates of Award: 01/2012-06/2013

Yearly Direct Costs of Award: $50,000

Role: Study principal investigator

Percent effort: 50% (for study in total)

Title: ‘Enhancing Tumor-Associated Antigen Cytotoxic T-Cell Immunotherapy in Patients with Relapsed/Refractory Wilms Tumor’

Funding Agency: Cannonball Kids' Cancer Research Grant

Dates of Award: 01/01/2020 – 12/31/2022

Yearly Direct Costs of Award: $66,666

Role: Study principal investigator

Percent effort: 10%

Title: ‘‘Targeting Solid Tumors with Multi-antigen Specific T cells by Identifying the Genetic and Epigenetic Determinants of Therapeutic Response’

Funding Agency: Braden’s Hope for Childhood Cancer Grant Award (Mercy collaboration)

Dates of Award: 11/01/2019 – 11/1/2022

Yearly Direct Costs of Award: $50,000

Role: Co-investigator

Percent effort: 7%

Publications

Selected Peer-Reviewed Publications

Meloni-Ehrig AM, Tirado CA, Chen K, Jahn J, Suchan S, Scheerle J, Crosby MG, Meany H, et al: Isolated del(14)(q21) in a case of precursor B-cell acute lymphoblastic leukemia. Cancer Genet Cytogenet 161:82-5, 2005.

Meany HJ, Gidvani VK, Minniti CP: Utility of PET scans to predict disease relapse in pediatric patients with Hodgkin lymphoma. Pediatr Blood Cancer 48:399-402, 2007.

Meany HJ, Seibel NL, Sun J, et al: Phase 2 trial of recombinant tumor necrosis factor-alpha in combination with dactinomycin in children with recurrent Wilms tumor. J Immunother 31:679-83, 2008.

Meany HJ, Fox E, McCully C, et al: The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates. Cancer Chemother Pharmacol 62:387-92, 2008.

Meany HJ, Warren KE, Fox E, et al: Pharmacokinetics of temozolomide administered in combination with O(6)-benzylguanine in children and adolescents with refractory solid tumors. Cancer Chemother Pharmacol. 65:137-42, 2009.

Meany HJ, Sackett DL, Maris JM, et al: Clinical outcome in children with recurrent neuroblastoma treated with ABT-751 and effect of ABT-751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitro. Pediatr Blood Cancer. 54:47-54, 2010.

Meany H, Balis FM, Aikin A, et al: Pediatric Phase I Trial Design Using Maximum Target Inhibition as the Primary Endpoint. J Natl Cancer Inst. 2010 Jun 16;102(12):909-12.

White J, Meany H: Neuroblastoma: An Unusual Diagnosis for a Pediatric Retropharyngeal Mass. International Journal of Pediatric Otorhinolaryngology Extra. 6(2):62-4, 2011.

Meany H, Dombi E, Reynolds J, et al: 18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST). Pediatr Blood Cancer. 2013 Jan;60(1):59-64.

Fox E, Mosse Y, Meany H, et al: Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: A report from the Children’s Oncology Group (ANBL0621). Pediatr Blood Cancer. 2014 Jun;61(6):990-6.

Weaver M, Navid F, Meany HJ, et al: Vincristine and Dactinomycin in Infantile Myofibromatosis with a Review of Treatment Options. J Pediatr Hematol Oncol. 2015 Apr:37(3):237-41.

Meany HJ, London WB, Ambros PF, et al: Significance of Clinical and Biologic Features in Stage 3 Neuroblastoma: A Report from the International Neuroblastoma Risk Group Project. Pediatr Blood Cancer. 2014 Nov;61(11):1932-9.

Meany HJ, Seibel NL, Krailo M, et al: Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (anti-CD19) Immunotoxin with Standard Induction Chemotherapy in Children and Adolescents with Relapsed B-lineage ALL. A report from the Children’s Oncology Group. J Immunother. 2015 Sep:38(7):299-305.

Kwatra NS, Meany HJ, Ghelani SJ, Zahavi D, Pandya N, Majd M. Glomerular hyperfiltration in children with cancer: prevalence and a hypothesis. Pediatr Radiol. 2017 Feb;47(2):221-226.

Will N, Whitehead MT, Meany HJ, Reilly BK. A 6-year-old presenting with headache and post-auricular pain. Am J Otolaryngol. 2017 Mar - Apr;38(2):248-250.

Hinds PS, Wang J, Stern ED, Macpherson CF, Wharton CM, Okorosobo R, Cheng YI, Gross HE, Meany HJ, Jacobs S. Voices of children and adolescents on phase 1 or phase 2 cancer trials: A new trial endpoint? Cancer. 2017 Jun 5.

Carden MA, Smith S, Meany H, Yin H, Alazraki A, Rapkin LB. Platinum plus bortezomib for the treatment of pediatric renal medullary carcinoma: Two cases. Pediatr Blood Cancer. 2017 Jul;64(7).

See comment in PubMed Commons below

Ari P, Kars M, Meany H, Pestieau S. Treatment of Transient Peripheral Neuropathy During Chimeric 14.18 Antibody Therapy in Children With Neuroblastoma: A Case Series.J Pediatr Hematol Oncol. 2017 Jul 3.

Twist CJ, Naranjo A, Schmidt ML, Tenney SC, Cohn SL, Meany HJ, et al. Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531. J Clin Oncol. 2018 Nov 16:JCO1800419. doi: 10.1200/JCO.18.00419. [Epub ahead of print].

Adamson PC, Veal GJ, Womer RB, Meany HJ, Bernhardt MB, Frazier AL, Balis FM. Fundamental problems with pediatric adaptive dosing of carboplatin using nuclear-medicine-based estimates of renal function. Pediatr Blood Cancer. 2019 Jun;66(6):e27672.

Meany HJ. Non-High-Risk Neuroblastoma: Classification and Achievements in Therapy. Children (Basel). 2019 Jan 8;6(1).

Hont AB, Cruz CR, Ulrey R, Meany HJ. Immunotherapy of Relapsed and Refractory Solid Tumors with Ex Vivo Expanded Multi-Tumor Associated Antigen Specific Cytotoxic T Lymphocytes: A Phase I Study. J Clin Oncol. 2019 Sep 37 (26), 2349-2359.

Talbet JH, McGrath JL, Manrique M, Mantilla-Rivas E, Meany HJ, Oh AK, Rogers GF. Epithelioid Sarcoma in a Young Child: A Case Report and Literature Review. Plast Reconstr Surg Glob Open. 2021 Feb 1;9(2):e3377.

Meany HJ, Widemann BC, Pamela S Hinds, et al, Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors. Pediatr Blood Cancer. 2021 Nov;68(11):e29282. Epub 2021 Aug 12

Presentations or Posters

Meany HJ, Fox E, Aikin A, et al: Pediatric phase I trial design using a pharmacodynamic marker as the primary endpoint. American Society of Clinical Oncology Annual Meeting. Chicago, IL 2008. Selected for oral poster discussion session.

Doros L, Meany H: Adolescent with Metastatic Colorectal Signet-Ring Cell Carcinoma with Progression when Transitioned from First-line to Maintenance Therapy. American Society of Pediatric Hematology/Oncology Annual Meeting, Montreal, Quebec, Canada 2010.

Meany H, Reynolds J, Whatley M, et al: Evaluation of PN and MPNST with FDG-PET on a NF1 Natural History Study. Children’s Tumor Foundation Annual NF Conference. Bethesda, MD 2010.

Meany HJ, Attiyeh E, Naranjo A, et al: Outcome Analysis of Non-high-Risk Neuroblastoma Patients Enrolled on Children’s Oncology Group Trials P9641 and A3961. American Society of Clinical Oncology Annual Meeting. Chicago, IL 2012. Selected for oral poster discussion session.

Meany HJ, Attiyeh E, Naranjo A, et al: Outcome Analysis of Non-high-Risk Neuroblastoma Patients Enrolled on Children’s Oncology Group Trials P9641 and A3961. Advances in Neuroblastoma Research Conference. Toronto, Canada 2012. Selected for oral presentation.

Meany HJ, Hinds PS, Bagatell R, et al: Phase 1 Study of Sorafenib and Irinotecan in Pediatric Patients with Relapsed or Refractory Solid Tumors. American Society of Clinical Oncology Annual Meeting. Chicago, IL 2014.

Bhaumik S, Meany HJ, Akshintala S, et al: Identification and Management of Lesions Concerning for Transformation to Malignant Peripheral Nerve Sheath Tumors (MPNST) in Neurofibromatosis 1 (NF1). Children’s Tumor Foundation Neurofibromatosis Conference. Washington, DC 2014.  Selected for oral poster discussion session.

Bhaumik S, Meany H, Choyke P, et al: Early detection of Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1. Children’s Tumor Foundation Neurofibromatosis Conference. Monterey, CA 2015.

Bhaumik S, Meany H, Choyke P, et al: Early detection of Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1. American Society of Clinical Oncology Annual Meeting. Chicago, IL 2015.

Weigel B, Banerjee A, Meany H, et al: Phase 1 Study Evaluating the Safety and Pharmacokinetics of Panitumumab in Children With Solid Tumors. American Society of Pediatric Hematology/Oncology Annual Meeting. Minneapolis, MN 2016.

Nelson M, Meany H: Hepatocellular Carcinoma and Niemann-Pick Diease Type C: an Insidious Menace with Potential For Screening? American Society of Pediatric Hematology/Oncology Annual Meeting. Minneapolis, MN 2016.

Sebastian T, Fishbein T, Meany H: Hepatocellular Carcinoma in a Patient with Niemann Pick Disease Type C. World Congress of Pediatric Gastroenterology, Hepatology and Nutrition. Montreal, Canada 2016.

Houghtelin A, Cruz CR, Meany H:  Ex vivo Expanded Multi-Antigen Specific Lymphocytes for the Treatment of Solid Tumors. Annual Pediatric Blood and Marrow Transplant Consortium Meeting Montreal, Canada 2017.

Houghtelin A, Cruz CR, Meany H:  Ex vivo Expanded Multi-Antigen Specific Lymphocytes for the Treatment of Solid Tumors. Congress of the International Society of Paediatric Oncology, Washington, DC 2017.

Nelson MV, Yock TI, Wolden SL, Wang J, Cheng YI, Hess CB, Kim A, Meany HJ, et al. High Incidence of Local and Regional Failure in Pediatric Rhabdomyosarcoma of the Nasal Ala. American Society for Radiation Oncology Annual Meeting 2019. Chicago IL.

Christopher A, John L, Meany H, Hougen T, Sinha P, Olivieri L. Characterization of a Pediatric Intrapericardial Malignant Rhabdoid Tumor by Multiparametric CMR Imaging. Society for Cardiovascular Magnetic Resonance 22^nd Annual Scientific Sessions. Bellevue, WA 2019.

Book Chapters

Meany HJ, Ratner N, Widemann B. Malignant Peripheral Nerve Sheath Tumors (MPNST): prognostic and diagnostic markers and therapeutic targets. Neurofibromatosis type1 Molecular and Cellular Biology, Chapter 29. Springer 2012.

Meany H, Kim, AE, Dome J. Chemotherapy and Multidisciplinary Approaches To Pediatric Sarcoma. Sarcoma. A Multidisciplinary Approach to Treatment Chapter 10. Springer International Publishing 2017.

Meany H, Bagatell R. Neuroblastoma. Rudolph’s Pediatrics. Chapter 453. McGraw Hill Education. 2018.

Presentations

International

‘Non High-risk Neuroblastoma Task Force Report’

Children’s Oncology Group- Group Meeting; Neuroblastoma Committee General Meeting

Spring and Fall Meetings beginning March 2010 - September 2012

‘ANBL1232: Utilizing Response and Biology Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma’

Children’s Oncology Group- Group Meeting; Neuroblastoma Committee General Meeting

Spring and Fall Meetings beginning April 2013 – present

‘Low and Intermediate Risk Neuroblastoma’

Neuroblastoma Parent Global Symposium 2020: Children’s Neuroblastoma Cancer Foundation, Solving Kids’ Cancer (UK), Solving Kids’ Cancer (US)

November 7, 2020

National

‘Phase 1 Clinical Trials and Drug Development’

Children’s Hospital of Los Angeles Hematology-Oncology Grand Rounds, Los Angeles, California

March, 2011

‘Phase 1 Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients with Relapsed or Refractory Solid Tumors’

Pablove Foundation Brain Tumor Symposium, Los Angeles, California

November, 2012

‘Innovations in Pediatric Phase I Trial Design’

Seattle Children’s Hospital, Hematology-Oncology Lecture Series, Seattle, Washington

May, 2015

‘Pediatric Solid Tumor Malignancies’

Pediatric Grand Rounds

MetroHealth Medical Centerealth , Cleveland Ohio

January 7, 2021

Regional

‘Pediatric Head and Neck Malignancies’

Children’s National Medical Center

April, 2009

‘Phase I Clinical Trial Development in Pediatric Patients’

Children’s National Medical Center

November, 2010

‘Phase 1 Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients with Relapsed or Refractory Solid Tumors’

Center for Cancer and Blood Disorders of Northern Virginia, Falls Church, Virginia

April, 2012

‘Insulin-like Growth Factor 1 Receptor (IGF-1R) Monoclonal Antibodies in the Treatment of Ewing Sarcoma’

Children’s National Medical Center

March, 2015

‘Clinical Update on Neuroblastoma’

The Children’s Cancer Foundation, Inc. 3rd Annual Research Symposium, Landover, MD

June, 2018

Oncology Review Lecture

Pediatric Board Review Course

George Washington University

2015-2018

Peer Review Activity

Journal Reviewer

Pediatric Blood and Cancer

Journal of Clinical Oncology

British Journal of Cancer

Cancer Chemotherapy and Pharmacology

Journal of Pediatric Hematology-Oncology

British Medical Journal

Cancer